By Michele Maatouk
Date: Friday 21 Aug 2026
(Sharecast News) - Pharmaceutlcal firms Moderna and MSD (Merck Sharp & Dohme (UK) Limited) said on on Wednesday that a personalised mRNA melanoma vaccine they are jointly developing had shown positive results in a first-ever late-stage trial.
No recent information was found.
| Currency | US Dollars |
| Share Price | $ 148.69 |
| Change Today | $ 0.00 |
| % Change | 0.00 % |
| 52 Week High | $156.45 |
| 52 Week Low | $78.58 |
| Volume | 3,664 |
| Shares Issued | 2,474.63m |
| Market Cap | $367,952m |
| RiskGrade | 92 |
You are here: research